Global Wealth Management Investment Advisory Inc. Raises Stake in AbbVie Inc. $ABBV

Global Wealth Management Investment Advisory Inc. increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 7.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,555 shares of the company’s stock after acquiring an additional 3,339 shares during the period. AbbVie makes up 1.8% of Global Wealth Management Investment Advisory Inc.’s investment portfolio, making the stock its 16th largest holding. Global Wealth Management Investment Advisory Inc.’s holdings in AbbVie were worth $10,548,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in ABBV. Vanguard Group Inc. raised its stake in AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after buying an additional 3,380,842 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of AbbVie by 2.4% during the second quarter. Geode Capital Management LLC now owns 39,178,351 shares of the company’s stock valued at $7,240,169,000 after acquiring an additional 924,761 shares in the last quarter. Charles Schwab Investment Management Inc. raised its position in shares of AbbVie by 6.0% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 26,783,329 shares of the company’s stock worth $4,970,848,000 after purchasing an additional 1,517,222 shares during the last quarter. Norges Bank bought a new position in AbbVie in the 2nd quarter worth about $4,288,200,000. Finally, Raymond James Financial Inc. grew its position in AbbVie by 41.8% during the 2nd quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock valued at $1,733,222,000 after purchasing an additional 2,753,312 shares during the last quarter. Institutional investors own 70.23% of the company’s stock.

Wall Street Analyst Weigh In

ABBV has been the topic of several analyst reports. Citigroup dropped their target price on shares of AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research note on Monday, November 3rd. Evercore ISI boosted their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a report on Monday, September 22nd. Raymond James Financial set a $256.00 target price on AbbVie in a research note on Monday, November 3rd. Scotiabank started coverage on AbbVie in a report on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 target price for the company. Finally, Guggenheim upped their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and eight have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $246.89.

AbbVie Price Performance

NYSE ABBV opened at $220.51 on Wednesday. The stock has a market capitalization of $389.72 billion, a price-to-earnings ratio of 167.05, a PEG ratio of 0.92 and a beta of 0.36. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The business’s fifty day moving average price is $226.84 and its 200-day moving average price is $216.04.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the previous year, the company posted $3.00 earnings per share. AbbVie’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date of this dividend is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s payout ratio is currently 496.97%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a three‑year drug‑pricing agreement with the White House that grants exemptions from certain tariffs and future pricing mandates in exchange for lower Medicaid pricing and a pledge to invest $100 billion in U.S. R&D and capital over the next decade — market sees tariff relief and large domestic investment as net positives for cash flow visibility and political risk reduction. AbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge
• Positive Sentiment: AbbVie agreed to an exclusive global licensing/partnering deal for RC148 (a PD‑1/VEGF bispecific) with RemeGen — up to ~$5.6B — boosting its oncology pipeline and giving upside to future sales if the asset progresses. AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle
• Positive Sentiment: Operational and manufacturing expansion: AbbVie is acquiring an Arizona drug‑delivery/manufacturing facility and the SmartDose on‑body system rights from West Pharma, and announced a $175M investment in an Arizona drug‑device plant — these moves support supply security, onshoring and next‑gen product delivery capacity. AbbVie to Acquire Drug Delivery System, Arizona Manufacturing Facility from West Pharma
• Neutral Sentiment: Regulatory engagement: AbbVie (with peers) is leading calls for the FDA to update post‑approval change rules — potential long‑run operational implications, but not an immediate earnings driver. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Neutral Sentiment: Clinical pipeline progress: Phase‑2 readout/trial completion for ABBV‑932 (bipolar depression) was reported — positive for pipeline optionality but early stage and uncertain commercial timing. AbbVie’s ABBV-932 Bipolar Depression Trial Reaches Completion
• Neutral Sentiment: Analyst / retail attention: Several bullish analyst pieces and increased investor searches highlight AbbVie’s dividend and value characteristics — supportive sentiment but not a direct fundamental change. Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
• Negative Sentiment: Revenue and margin risk from price concessions: the White House pact requires lower Medicaid pricing and expanded affordable patient offerings, which could blunt near‑term revenue/margin growth for products used widely in public programs — investors will watch guidance and product‑level impact. Abbvie, US reach agreement to cut drug prices

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.